Outcomes Study Reports Use of MelaFind Reduced Benign Biopsies by 61% in Patients at Risk for Melanoma (MELA Sciences Inc)

(Source: MELA Sciences Inc) For Immediate Release Outcomes Study Reports Use of MelaFind Reduced Benign Biopsies by 61% in Patients at Risk for Melanoma Irvington, NY,October 21, 2014- MELA Sciences, Inc. (NASDAQ: MELA), developer ofMelaFind®, a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional info to help them decide whether or not to biopsy (at the most curable and cost-effective stage), today announced that highly favorable results were obtained in a study using MelaFind to assess lesions in patients at risk for melanoma. The results were included in the,...